Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490809 | 0.87 | ALDH1A1 (0.69) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL18171795 | 0.84 | ALDH1A1 (0.66) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL28985491 | 0.82 | ALDH1A1 (0.63) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL8139631 | 0.82 | L3MBTL1 (0.64) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL444328 | 0.81 | STAT3 (0.65) | MAPTALDH1A1KDM4EALOX5MEN1 | |
| SCHEMBL28247078 | 0.80 | PRMT5 (0.48) | MAPTALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL8528645 | 0.80 | ALDH1A1 (0.71) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL28428521 | 0.78 | ALDH1A1 (0.58) | MAPTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL10244867 | 0.78 | CYP19A1 (0.50) | MAPTALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL2086881 | 0.78 | KDM4E (0.76) | MAPTALDH1A1NPSR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7304079-B2 | Preparing 3-benzothiazolylalkyl-1-indolylacetic acids and esters by cyclizing a 3-(anilinothiocarbonylalkyl)-1-indolylacetic ester with potassium ferricyanide or sodium hydride, optionally deprotecting the acid group; aldose reductase inhibitors for diabetic complications; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304079-B2 | Preparing 3-benzothiazolylalkyl-1-indolylacetic acids and esters by cyclizing a 3-(anilinothiocarbonylalkyl)-1-indolylacetic ester with potassium ferricyanide or sodium hydride, optionally deprotecting the acid group; aldose reductase inhibitors for diabetic complications; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070093530-A1 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2007-04-26 | — | — | US | disclosed |
| US-20070093530-A1 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | MAPT 4550/4885ALDH1A1 513/4885LMNA 4301/4885 |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | MAPT 4218/4885ALDH1A1 338/4885LMNA 3538/4885 |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | MAPT 4550/4885ALDH1A1 513/4885LMNA 4301/4885 |
| US-20070093530-A1 | SUBSTITUTED INDOLEALKANOIC ACIDS | GPR119, AANAT, AADAT | MAPT 4218/4885ALDH1A1 338/4885LMNA 3538/4885 |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | MAPT 4218/4885ALDH1A1 338/4885LMNA 3538/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | MAPT 4218/4885ALDH1A1 338/4885LMNA 3538/4885 |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | AKR1C3, AKR1C2, AKR1B1 | MAPT 334/4885ALDH1A1 31/4885LMNA 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.